Although there is no hard-and-fast rule about what constitutes a blue-chip stock, they all tend to have certain qualities. They are large, financially stable companies that have been through numerous
Institutional investors represent the so-called big money that wields significant influence over the stock market. That influence manifests in many ways.
The Investment Committee discuss the latest Calls of the Day.
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
If you're wondering which overvalued blue-chip stocks to ditch right now, look no further. The best investors pay attention to a stock's valuation.
Eli Lilly sells two of the most sought-after treatments -- those prescribed for weight management. Mounjaro and Zepbound are driving double-digit earnings growth at the big pharma company.
New  $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India GENEVA , May 29, 2024 /PRNewswire/ -- During the World Health Assembly toda
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
INDIANAPOLIS , May 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson, execut
Eli Lilly stock could reach $1,001 per share, according to a Wall Street analyst from BMO Capital. Tirzepatide sales are off the charts but could be much higher if not for supply constraints.
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the
Vertex Pharmaceuticals is in the midst of a major diversification plan. Eli Lilly's medicines for diabetes and obesity are incredibly hot sellers.
Some analysts estimate that anti-obesity medications could grow into a $100 billion industry by the end of the decade. Companies including Calibrate, Ro and WeightWatchers are looking to capitalize on

3 High-Flying Stocks That Could Soar Even More

06:47am, Saturday, 25'th May 2024
Eli Lilly is just getting started with its powerful obesity drug and a loaded pipeline. It's not too late to invest in scorching-hot Novo Nordisk.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE